Human Immunodeficiency Virus disease and cardiac surgery – where are we?

Uncertainties concerning the effects of cardiopulmonary bypass, outcome and possibility of operator injury slowed progress in cardiac surgery in the HIV-infected patient. Severely ill patients, some with AIDS and others probably with AIDS, formed the basis of early reports; it was shown they could b...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	David Blyth
Formato:	article
Lenguaje:	EN
Publicado:	South African Heart Association 2017
Materias:	human immunodeficiency virus cardiac surgery hiv Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/4570d80fd6714d7aa9c93bac6eff93ba
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4570d80fd6714d7aa9c93bac6eff93ba
record_format	dspace
spelling	oai:doaj.org-article:4570d80fd6714d7aa9c93bac6eff93ba2021-11-22T08:58:33ZHuman Immunodeficiency Virus disease and cardiac surgery – where are we?10.24170/6-4-19731996-67412071-4602https://doaj.org/article/4570d80fd6714d7aa9c93bac6eff93ba2017-04-01T00:00:00Zhttps://www.journals.ac.za/index.php/SAHJ/article/view/1973https://doaj.org/toc/1996-6741https://doaj.org/toc/2071-4602Uncertainties concerning the effects of cardiopulmonary bypass, outcome and possibility of operator injury slowed progress in cardiac surgery in the HIV-infected patient. Severely ill patients, some with AIDS and others probably with AIDS, formed the basis of early reports; it was shown they could be taken through surgery satisfactorily. Following the advent of antiretroviral monotherapy – zidovudine, an NRTI – in 1987, and dual therapy in the early 1990s with NRTIs, the addition of protease inhibitors (PI) in 1995, although a double-edged sword, led to triple therapy/HAART, (2 NRTIs and a PI) and startling improvement in morbidity and mortality in markedly compromised HIV patients. Yet, it was only in 2003 when sizeable reports carrying ARV usage began to emerge. Intravenous drug addiction causing left-sided valvular heart disease was initially responsible for most cases, but there was now an increase in coronary artery disease (CAD) in young patients, blamed partly on lipid disturbances caused by PI. With an ARV rollout in South Africa delayed to 2004, and PIs only used in second line therapy in State-administered treatment, the increase in coronary artery disease has not been noted. The need for surgery in pericardial disease is rare. Paediatric cardiac surgery has been rarely reported, but is locally carried out; a new approach to medical management of these children should lead to more frequent surgery. Heart transplantation lags far behind solid organ transplantation, but there are indications that it will be more readily accepted. Certain vascular pathologies appear to be peculiar to HIV, with the virus itself being able to enter vessel walls with evolution of vascular disease. PIs would appear to accelerate coronary artery disease, as seen in younger HIV patients, who develop abnormal lipid profiles. The approach to cardiac surgery in most cardiac teaching units is looked at. Many answers have been found, but new issues have also arisen, as in relation to ARV’s and CAD. Most importantly, attitudes are changing: some would accept selected patients with AIDS not receiving ARVs. Very good results have followed surgery in patients who have suffered AIDS defining conditions but are stable on ARVs.David BlythSouth African Heart Associationarticlehuman immunodeficiency viruscardiac surgeryhivDiseases of the circulatory (Cardiovascular) systemRC666-701ENSA Heart Journal, Vol 6, Iss 4, Pp 210-221 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	human immunodeficiency virus cardiac surgery hiv Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	human immunodeficiency virus cardiac surgery hiv Diseases of the circulatory (Cardiovascular) system RC666-701 David Blyth Human Immunodeficiency Virus disease and cardiac surgery – where are we?
description	Uncertainties concerning the effects of cardiopulmonary bypass, outcome and possibility of operator injury slowed progress in cardiac surgery in the HIV-infected patient. Severely ill patients, some with AIDS and others probably with AIDS, formed the basis of early reports; it was shown they could be taken through surgery satisfactorily. Following the advent of antiretroviral monotherapy – zidovudine, an NRTI – in 1987, and dual therapy in the early 1990s with NRTIs, the addition of protease inhibitors (PI) in 1995, although a double-edged sword, led to triple therapy/HAART, (2 NRTIs and a PI) and startling improvement in morbidity and mortality in markedly compromised HIV patients. Yet, it was only in 2003 when sizeable reports carrying ARV usage began to emerge. Intravenous drug addiction causing left-sided valvular heart disease was initially responsible for most cases, but there was now an increase in coronary artery disease (CAD) in young patients, blamed partly on lipid disturbances caused by PI. With an ARV rollout in South Africa delayed to 2004, and PIs only used in second line therapy in State-administered treatment, the increase in coronary artery disease has not been noted. The need for surgery in pericardial disease is rare. Paediatric cardiac surgery has been rarely reported, but is locally carried out; a new approach to medical management of these children should lead to more frequent surgery. Heart transplantation lags far behind solid organ transplantation, but there are indications that it will be more readily accepted. Certain vascular pathologies appear to be peculiar to HIV, with the virus itself being able to enter vessel walls with evolution of vascular disease. PIs would appear to accelerate coronary artery disease, as seen in younger HIV patients, who develop abnormal lipid profiles. The approach to cardiac surgery in most cardiac teaching units is looked at. Many answers have been found, but new issues have also arisen, as in relation to ARV’s and CAD. Most importantly, attitudes are changing: some would accept selected patients with AIDS not receiving ARVs. Very good results have followed surgery in patients who have suffered AIDS defining conditions but are stable on ARVs.
format	article
author	David Blyth
author_facet	David Blyth
author_sort	David Blyth
title	Human Immunodeficiency Virus disease and cardiac surgery – where are we?
title_short	Human Immunodeficiency Virus disease and cardiac surgery – where are we?
title_full	Human Immunodeficiency Virus disease and cardiac surgery – where are we?
title_fullStr	Human Immunodeficiency Virus disease and cardiac surgery – where are we?
title_full_unstemmed	Human Immunodeficiency Virus disease and cardiac surgery – where are we?
title_sort	human immunodeficiency virus disease and cardiac surgery – where are we?
publisher	South African Heart Association
publishDate	2017
url	https://doaj.org/article/4570d80fd6714d7aa9c93bac6eff93ba
work_keys_str_mv	AT davidblyth humanimmunodeficiencyvirusdiseaseandcardiacsurgerywherearewe
_version_	1718417790737580032

Human Immunodeficiency Virus disease and cardiac surgery – where are we?

Ejemplares similares